LTI-03: A Pioneering Compound Treatment for IPF
IPF is a chronic lung disease characterized by progressive tissue scarring that prevents proper lung function.
LTI-03 operates through a novel mechanism of action by targeting healthy epithelial cells and profibrotic proteins. LTI-03 promotes the protection of lung epithelium while inhibiting fibroblast growth and expansion.
LTI-03 is currently being evaluated in a Phase 1b clinical trial in patients recently diagnosed with IPF.